Skip to main content
NewslettersWatchlist

Okyo Pharma Limited ADR(OKYO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Okyo Pharma Limited ADR

Martello Court Admiral Park
St. Peter Port Y7 GY1 3HB
P: 44-20-7495-2379
http://www.okyopharma.com

Profile

OKYO Pharma Limited is a life sciences company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain. OKYO Pharma Limited is based in LONDON.

Key Executives

NameTitle
Gary S. JacobCEO/Director
Raj PatilChief Scientific Officer
Keeren ShahCFO

More from The Globe

The close: Stocks edge higher after Fed comments, ahead of Nvidia
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.
Before the Bell: What every Canadian investor needs to know today
Traders work on the floor of the New York Stock Exchange during morning trading on May 17, 2024 in New York City. Wall Street stocks opened little changed May 17 after pulling back from a record run where the Dow exceeded 40,000 points for the first time. Around 10 minutes into trading the Dow Jones Industrial Average was steady at 39,872.66. (Photo by ANGELA WEISS / AFP) (Photo by ANGELA WEISS/AFP via Getty Images)
ReconAfrica agrees to pay out more than $10-million over allegedly misleading disclosure
ReconAfrica oil drilling site in Namibia for Geoffrey York and Emma Graney story.
Dividend investing has lost its mojo. Here’s why – and how to adapt
Ian McGugan
The Globe Investing Club 2024: Let the competition begin!
opinion
Here’s the real reason your Canadian stocks can’t keep up
Tim Shufelt
Dow ends above 40,000 milestone, TSX also at fresh record high
Traders work on the floor of the New York Stock Exchange (NYSE) on May 16.
number cruncher
U.S technology stocks with earnings and price momentum
For Number Cruncher column in Globe Investor/ROB only.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.